Revolution Medicines, Inc. Warrant
Revolution Medicines, Inc. Warrant Q3 FY2025 earnings call
November 5, 2025 · fiscal period ended 2025-09
EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2025-11-05
Management highlights
• Pipeline progress: Continued advancement of 3 clinical stage RAS(ON) inhibitors. Daraxonrasib in pancreatic cancer has received 3 special designations. Clinical updates on daraxonrasib in pancreatic cancer including Phase I data, RASolute 302-304 trials. Elironrasib monotherapy data in G12C non-small cell lung cancer. RMC-5127 on track for first-in-human trial in Q1 2026. • Organizational appointments: Alan Sandler joined as Chief Development Officer; Alicia Gardner and Gerwin Winter in key commercial roles. • Financials: Ended Q3 2025 with $1.93B in cash and investments. R&D and G&A expenses increased. Projected full-year 2025 GAAP net loss between $1.03B and $1.09B.
Segment performance
No detailed product segment financial performance with revenue contribution provided in the transcript.
Guidance
• Reiterated 2025 financial guidance, expecting full-year 2025 GAAP net loss to be between $1.03 billion and $1.09 billion, including noncash stock-based compensation expense between $115 million and $130 million.
Risks
No specific risks discussed beyond the standard forward-looking statement disclaimer noting actual results may differ from forward-looking statements.
Q&A highlights
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | — | — | — | — |
| Revenue | — | — | — | — |
Transcript
November 5, 2025Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.